<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01083888</url>
  </required_header>
  <id_info>
    <org_study_id>1517-CL-0203</org_study_id>
    <nct_id>NCT01083888</nct_id>
  </id_info>
  <brief_title>ASP1517 Pharmacokinetics Study in Anemia Patients on Hemodialysis</brief_title>
  <official_title>ASP1517 Clinical Pharmacological Study Examination of Pharmacokinetics and Pharmacodynamics in Patients With Renal Anemia Undergoing Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the Pharmacokinetics and pharmacodynamics of single doses of ASP1517 in renal
      anemia patients on hemodialysis. Safety and tolerability will be also evaluated in these
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2010</start_date>
  <completion_date type="Actual">June 7, 2010</completion_date>
  <primary_completion_date type="Actual">June 7, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ASP1517 concentrations in plasma</measure>
    <time_frame>For 96 hours after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ASP1517 concentrations in dialysate</measure>
    <time_frame>For 6 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma EPO level</measure>
    <time_frame>Pre dosing and for 24 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by Adverse Event, vital signs standard 12-lead ECG or lab tests</measure>
    <time_frame>For 96 hours after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Anemia</condition>
  <condition>Hemodialysis</condition>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>1 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single oral dose of ASP1517 on Days 1 and 8</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>roxadustat</intervention_name>
    <description>oral</description>
    <arm_group_label>1 group</arm_group_label>
    <other_name>ASP1517</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic renal failure patients receiving hemodialysis thrice weekly

          -  Body weight: &gt;=40.0 and &lt;80.0 kg

          -  Mean hemoglobin level &gt;=10.0 and =&lt;12.0 g/dL

        Exclusion Criteria:

          -  Patients with severe inflammation or infection

          -  Patients who have a medical history of gastrointestinal surgery or enterectomy

          -  Patients who have uncontrolled hypertension

          -  Patients whose AST, ALT, total bilirubin, GGT exceed the ULN or those who have a
             medical history of serious liver diseases

          -  Patients who have a medical history of severe cardiac or cerebrovascular diseases

          -  Patients who have received blood transfusion or who have had a surgery (except surgery
             for a shunt) within 4 weeks

          -  Patients with a medical history of serious drug allergies

          -  Patients who may be pregnant or lactating, or who refuse to use required birth control
             during the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chubu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://astellasclinicalstudyresults.com/study.aspx?ID=353</url>
    <description>Link to results on Astellas Clinical Study Results website</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 8, 2010</study_first_submitted>
  <study_first_submitted_qc>March 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2010</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FG-4592</keyword>
  <keyword>ASP1517</keyword>
  <keyword>Safety and tolerability</keyword>
  <keyword>Plasma concentration</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under &quot;Sponsor Specific Details for Astellas.&quot;</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

